Fig. 1 · Structure

Documents & Downloads

17-Hydroxyprogesterone

Cat. No. A15860 CAS 68-96-2

Steroid Hormone

17-Hydroxyprogesterone is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.

In Stock

Publications for 17-Hydroxyprogesterone

2 publications citing this product

  1. Huo, G, .et al. , Appl. Phys. A, 2020, 126, 111
  2. Zhang J, .et al. , 3 Biotech, 2020, Feb;10(2):35 PMID: 31988829

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

17-OHP promoted coactivator recruitment by the human GR ligand-binding domain, with a reported EC50 of 7.14 μM. Cellular reporter and target-gene experiments supported GR activation under the tested conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Human Endogenous Metabolite  

17-Hydroxyprogesterone Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of 17-Hydroxyprogesterone from 1 published reference. In vivo models include male C57BL/6 mice.

17-Hydroxyprogesterone In Vitro Studies

In HepG2 cells, 0.1–1 μM 17-OHP increased GR reporter activity after 24 hours. Receptor-domain deletion abolished this response. In mouse primary hepatocytes, RU486 suppressed 17-OHP-induced GR target-gene expression; tested alternative nuclear-receptor reporters were not activated. [1]

GR coactivator recruitment

Biochemical assay · Cell-free human recombinant GR ligand-binding domain and fluorescent coactivator peptide [1]

17-OHP promoted GR coactivator recruitment; this functional EC50 is not an equilibrium binding constant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GR ligand-binding-domain coactivator recruitmentEC50 7.14 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
20 minutes
Method
LanthaScreen TR-FRET GR coactivator assay; dexamethasone comparator
Reported limits
Assay vehicle and number of independent FRET determinations are not specified in the relevant text/caption.
Methods and source locations

Compound reported in the paper: 17-Hydroxyprogesterone; Compound label in the paper: 17-OHP

Evidence applies to the named unesterified research compound, not caproate/acetate derivatives or validation of A15860 lots.

Figure 1I; Results: 17-OHP activates GR in hepatocytes; Methods: Ligand-binding analysis

GR ligand-binding-domain coactivator recruitment: Sigmoidal dose-response fit; reported in Results, not estimated from the curve. — Figure 1I and corresponding Results paragraph

Cellular validation of GR activation

Cell-based study · Human HepG2 reporter cells; mouse primary hepatocytes [1]

17-OHP increased GR reporter activity and GR target-gene expression. Loss of GR DNA- or ligand-binding domains abolished reporter activation; RU486 suppressed target-gene induction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GR transcriptional activation and target-gene inductionIncreased versus vehicle; suppression by receptor-domain deletion or RU486[1]
Other nuclear-receptor responses under the tested conditionsNo activation of ARE, ERE, FXRE or LXRE reporters[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 and 1 μM 17-OHP in reporter and target-gene assays; 0.1 μM in localization/ChIP assays
Exposure duration
24 hours for reporters; 16 hours for target-gene assays; 1 hour for localization and ChIP
Method
GRE/PEPCK luciferase reporters, qPCR, subcellular Western blot and GR ChIP
Vehicle
Ethanol control
Co-treatment
Figure 1F: 10 μM RU486 pretreatment for 2 hours, followed by 1 μM 17-OHP for 16 hours
Reported limits
Do not interpret plotted replicates as independent biological experiments; caption does not define that level of replication.
Methods and source locations

Compound reported in the paper: 17-Hydroxyprogesterone; Compound label in the paper: 17-OHP

Evidence applies to the named unesterified research compound, not caproate/acetate derivatives or validation of A15860 lots.

Figure 1A–H and caption; Methods: Cell culture, Luciferase reporter assays, RNA isolation and real-time qPCR, Western blots, ChIP; Supplemental Figure 1

GR transcriptional activation and target-gene induction: Renilla-normalized reporter assay; 36B4-normalized qPCR. RU486 also antagonizes PR; PR-expression controls are in Supplemental Figure 1E. — Figure 1A, B, D–F; Supplemental Figure 1E

Other nuclear-receptor responses under the tested conditions: Corresponding receptor/ligand positive controls are shown in Supplemental Figure 1A–D. This is a tested panel, not proof of universal selectivity. — Figure 1C; Supplemental Figure 1A–D

17-Hydroxyprogesterone In Vivo Studies

Daily intraperitoneal 17-OHP (50 mg/kg for 14 days) impaired glucose homeostasis and increased hepatic triglycerides in male C57BL/6 mice versus corn oil. Body weight, food intake, liver-injury markers and total cholesterol remained unchanged. These findings describe a metabolic adverse-effect model. [1]

Direct 17-OHP exposure and glucose homeostasis in mice

Animal study · Male C57BL/6 mice [1]

Direct dosing impaired glucose homeostasis and increased hepatic triglycerides, with several unchanged physiological and liver-injury endpoints. This is a metabolic adverse-effect model, not evidence of therapeutic efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Blood glucose, insulin tolerance and liver triglyceridesHigher glucose in fed, fasting and refed states; impaired glucose/insulin tolerance; increased hepatic triglycerides[1]
Body weight, food intake, plasma ALT/AST/bilirubin, hepatic and plasma total cholesterolNo significant difference reported[1]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily
Treatment course
14 days
Vehicle
Corn oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
17-OHP versus corn oil
50 mg/kg
Corn oil vehicleHigher blood glucose, plasma insulin and hepatic triglycerides; impaired glucose and insulin tolerance. Body weight, food intake, ALT, AST, bilirubin and total cholesterol were unchanged.[1]
17-OHP versus corn oil
Model: Male C57BL/6 mice; source age range 8–10 weeks in Methods
Reported limits: Supplemental caption gives inconsistent GTT timing: day 10 in the schedule but panel I also appears in the post-sacrifice analysis list. No exact curve-derived values are adopted.
Methods and source locations

Compound reported in the paper: 17-Hydroxyprogesterone; Compound label in the paper: 17-OHP

Evidence applies to the named unesterified research compound, not caproate/acetate derivatives or validation of A15860 lots.

Supplemental Figure 5A–P and caption (SI PDF page 8); Results: 17-OHP promotes hyperglycemia and insulin resistance in lean mice; Methods: Animal studies

Blood glucose, insulin tolerance and liver triglycerides: n=6 per group; mean ± SD. Blood glucose measured on day 8; GTT/ITT schedules given as days 10/12 in caption. Qualitative directions verified from the actual image. — Supplemental Figure 5H–N and caption

Body weight, food intake, plasma ALT/AST/bilirubin, hepatic and plasma total cholesterol: Vehicle-controlled comparisons; n=6 per group; mean ± SD. No exact values estimated from plots. — Supplemental Figure 5C–G, O–P and corresponding Results

17-OHP versus corn oil · Supplemental Figure 5A–P and caption (SI PDF page 8); Results: 17-OHP promotes hyperglycemia and insulin resistance in lean mice; Methods: Animal studies

Specifications

Manufacturer Adooq Bioscience
CAS Number 68-96-2
Applications

Steroid Hormone

Formula C21H30O3
Molecular Weight 330.46
Synonyms 17-OHP
SMILES
CC(=O)C1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 57 mg/mL (172.49 mM)
Water Insoluble
Ethanol 57 mg/mL (172.49 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

17-Hydroxyprogesterone Research References

  1. [1] Lu Y, Wang E, Chen Y, et al. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor Journal of Clinical Investigation (2020). PMID: 32510471 DOI: 10.1172/JCI134485 Source material

Publications

2 publications citing this product

  1. Huo, G, .et al. , Appl. Phys. A, 2020, 126, 111
  2. Zhang J, .et al. , 3 Biotech, 2020, Feb;10(2):35 PMID: 31988829

Added to your cart

View Cart Checkout
Loading...